Skip to content
  • Home
  • Journalists
    • Headlines
  • Community
    • Businesses
    • Jobs
    • Learning
    • Marketplace
  • Store
(@)

Gene-Sequencing Company Illumina to Sell Cancer Test Developer

The move came two days after a court upheld the Federal Trade Commission’s challenge to the deal on antitrust grounds.

Nicole Sperling
Author: Nicole Sperling

Written by

Nicole Sperling

in

Antitrust Laws and Competition Issues, Decisions and Verdicts, European Union, Federal Trade Commission, Genetic Engineering, Grail Inc, Illumina Inc, Mergers, Acquisitions and Divestitures, Regulation and Deregulation of Industry, Tests (Medical)
←Florida Republican Party Suspends Chairman, Demands Resignation Amid Rape Investigation
Trump Says Nevada Fake Electors Treated ‘Unfairly’ During Rally In Reno→

More posts

  • ABC Tells Judge That FCC Showed “Retaliatory Motive” By Ordering Early License Review Despite “Less Intrusive” Options

  • 911 calls released in Christa Pike’s botched execution

  • Christa Pike Didn’t Get Emergency Care For Over 30 Minutes After Botched Execution

  • The Memo: Trump critics allege abuse of power as Ilhan Omar’s home is raided

About Us


Support Us

Trademark & Copyright 1998 – 2025 · MOSAEC

  • Facebook
  • Instagram
  • LinkedIn
  • YouTube